ASH 2021 | MRD negativity assessed by flow cytometry associated with improved outcomes in NPM1-mutated AML
Sangeetha Venugopal, MD, University of Texas MD Anderson Cancer Center, Houston, TX, talks on an investigation into the prognostic value of measurable residual disease (MRD) assessed by multiparametric flow cytometry (MFC) in patients with newly diagnosed NPM1-mutated acute myeloid leukemia (AML). Currently, MRD is determined through the quantification of NPM1-mutated transcripts in this patient population and the value of MRD by MFC is not well elucidated. Nearly 250 patients who achieved complete remission (CR) or CR with incomplete count recovery (CRi) following chemotherapy treatment were included in the study. It was shown that achieving MRD-negativity by MFC at initial response was associated with improved outcomes regardless of therapy intensity. Larger studies are needed to continue this line of investigation. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
